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A retrospective analysis of patients with hypertrophic obstructive cardio- 
myopathy treated by left ventrieular myotomy and myectomy from 1972 to 1994 
is reported. There were 158 patients (81 male and 77 female) with a mean age 
of 50.2 (+_17.2) years (range 12 to 80 years). One hundred nine patients (69%) 
were 60 years of age or younger, and 49 patients (31%) were older than 60 
years. The overall mean follow-up period was 6.1 (+_4.8) years (range 0.1 to 
19.3 years) and was 94% complete with a cumulative total of 956 patient-years. 
Preoperative xertional dyspnea was present in 84%, chest pain in 70%, 
presyncope in 54%, syncope in 31%, and cardiac arrest in 5% of patients. 
Preoperative cardiac catheterization was done in 150 patients, with mitral 
regurgitation detected in 104 patients (67%). The average maximal provocable 
left ventricular outflow tract gradient was 118 (+-46) mm Hg (range 25 to 250 
mm Hg). The average preoperative echocardiographic gradient at rest was 64 
mm Hg, 20 mm Hg in the early postoperative p riod and 10 mm Hg in the late 
postoperative p riod. The mean septal thickness was 2.2 (---0.6) cm, 1.9 (-+0.7) 
cm in the early postoperative p riod (t7 < 0.05 vs preoperative) and 1.7 (+-0.5) 
cm in the late postoperative period (p < 0.05 vs preoperative). The overall 
30-day operative mortality rate was 3.2% (5/158), and 0% for 109 patients 60 
years of age or younger. Causes of death included myocardial infarction and 
left ventricular free wall rupture, myocardial failure from septal perforation, 
sepsis, cerebrovascular ccident caused by thromboembolism, and delayed 
cardiac tamponade in one patient each. Concomitant coronary artery bypass 
grafting was performed in 22 patients (19.3% of patients _>40 years of age) and 
mitral valve replacement in 5 patients (3.2%). One hundred nine patients 
(69%) are alive, 10 patients (6.3%) were lost to follow-up, and 39 patients died 
(24.7%, including operative deaths). Actuarial survivals at 1, 5, 10, and 15 years 
were 92.4% -+2.2% 85.4% +-3.1%, 71.5% -4.6%, and 46% -+9%, respectively. 
The overall inearized eath rate for discharged patients was 1.9%/pt-yr, and 
for cardiac related deaths it was 1.7%/pt-yr. Thirty-nine (36%) of the 109 
survivors received 18-adrenergic blockers, and 30 (28%) received calcium 
channel blockers. Ninety-four patients had improvement in New York Heart 
Association functional class, 10 had improvement in symptoms but not in 
functional class, and 5 had no improvement in functional class or symptoms. 
Neither preoperative hemodynamic values nor routine echocardiographic 
measurements significantly correlated with quality of postoperative r sults. 
Left ventricular myotomy and myectomy is a safe and reproducibly effective 
operative treatment for medically refractory hypertrophic obstructive cardio- 
myopathy, especially for patients 60 years of age or younger. Improvement in
functional class and symptoms can be expected in nearly all patients. The 
results of myotomy and myectomy serve as a standard for comparison with 
other interventions for medically refractory cardiomyopathy. (J THORAC 
CARDIOVASC SURG 1996;111:586-94) 
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T he management of medically refractory hypertro- phic obstructive cardiomyopathy (HOCM) has 
evolved since the introduction more than 30 years 
ago of transaortic left ventricular myotomy and 
myectomy (LVMM) 1 to include mitral valve re- 
placement, 2 dual chamber pacing with right ventric- 
ular preexcitation, 3' 4 and, most recently, induced 
infarction of the basal interventricular septum. 5 At 
present, however, the results of LVMM remain the 
standard by which the efficacy of alternative meth- 
ods of treatment, particularly in the long term, is 
judged. In this report, we detail the results of 
LVMM achieved at a single institution over a 22- 
year period. 
Methods 
Patients and preoperative assessment. The records of 
all patients with medically refractory HOCM treated with 
LVMM from 1972 to 1994 at Stanford University Medical 
Center were reviewed. There were 158 patients (84 male 
and 77 female patients) with a mean age of 50.2 (+17.2) 
years (range 12 to 80 years). The preoperative New York 
Heart Association functional classes of the patients are 
listed in Table I. Exertional dyspnea was present in 83%, 
chest pain in 70%, presyncope in 54%, syncope in 31%, 
and a history of cardiac arrest (caused by ventricular 
fibrillation) in 5% of patients. Preoperative cardiac cath- 
eterization was performed in 150 patients, and the hemo- 
dynamic values are summarized in Table II. Mitral regur- 
gitation on left ventriculography was detected in 104 
patients (67%), and significant coronary artery disease 
was identified in 22 of 114 patients (19.3%) 40 years old or 
older. 
M-mode echocardiography was performed before the 
operation, before discharge from the hospital, and within 
the first year after operation in all patients. The preoper- 
ative examination was routinely combined with transtho- 
racic two-dimensional study since 1978 and with Doppler 
estimation of left ventricular outflow tract (LVOT) gradi- 
ents since 1984. Measurements of diastolic interventricu- 
lar septal (IVS) and left ventricular posterior wall 
(LVPW) thickness were made from M-mode studies by 
methods previously described. 6 
Indications for surgical therapy. All patients had been 
treated with/3-adrenergic antagonists or calcium channel 
blocking agents, or both, before the operation. Operative 
intervention was recommended for patients who had 
persistent disabling symptoms and evidence of LVOT 
obstruction (at rest or on provocation, or both). Patients 
with angiographically significant coronary artery disease 
or structural abnormalities of the mitral valve (one with 
endocarditis and ruptured chordae, three with myxoma- 
tous degeneration a d ruptured chordae, one with chronic 
rheumatic valvulitis) underwent concomitant LVMM and 
coronary artery bypass grafting or mitral valve replace- 
ment (two patients required LVMM, bypass grafting, and 
valve replacement). Three patients with a clinical history 
of preoperative cardiac arrest received automatic implant- 
able defibrillators (the first in 1987). 
Table I. Preoperative NYHA functional class 
Patients 
NYHA 
class No. % 
I 4/158 2.5 
II 41/158 26 
III 100/158 63.3 
IV 13/158 8.2 
NYHA, New York Heart Association. 
Operative technique. The heart is exposed via a median 
sternotomy with ascending aortic cannulation and bicaval 
venous cannulation through the right atrium. Cardiopul- 
monary bypass is commenced with systemic ooling to 
approximately 30 ° C. A vent is placed in the main pulmo- 
nary artery. A 500 ml dose of cold (4 ° C) hyperkalemic 
crystalloid cardioplegic solution is infused once in the 
aortic root after placement of the aortic crossclamp. 
Additional myocardial protection is achieved with contin- 
uous cold pericardial irrigation with saline solution during 
the crossclamp interval. An oblique aortotomy is made, 
and the right coronary cusp of the aortic valve is retracted 
to expose the IVS. 
Inspection and palpation of the IVS are used to assess 
the site for septal resection. A horizontal mattress tay 
suture is then placed in the most prominent portion of the 
septum, and a ribbon retractor is inserted through the 
aortic valve to the left ventricular apex. Two parallel 
incisions are then made in the septum, beginning 3 to 5 
mm below the aortic anulus and directed toward the left 
ventricular apex. The first incision is made just to the right 
of the midpoint of the right coronary cusp and the second 
incision approximately 1 cm to the left. The length of 
these incisions is 3 to 4 cm and the maximum depth 
approximately 1 cm (individualized according to septal 
thickness). Injury to the mitral valve apparatus i avoided 
by cutting down onto the ribbon retractor. The interven- 
ing bar of muscle is then excised sharply with countertrac- 
tion applied to the previously placed stay suture. In 
patients with significant hypertrophy extending into the 
adjacent anterolateral free wall, a third incision is then 
made, beginning below the commissure between the left 
and right coronary leaflets and directed toward the base of 
the anterolateral papillary muscle. Septal tissue between 
this incision and the primary trough already created is 
sharply excised to further increase the cross-sectional area 
of the LVOT. The resection, as described, iscarried out to 
the maximum extent considered feasible, and for this 
reason neither intraoperative hemodynamic measure- 
ments nor transesophageal echocardiography is used to 
gauge the adequacy of relief of LVOT obstruction; no 
patient in this series has required reoperation because of 
a significant residual gradient. 
Postoperative management. Methods for early postop- 
erative management were routine, including administra- 
tion of inotropic drugs if indicated. If ¢3-adrenergic block- 
ing drugs had been administered before the operation, 
these were continued at decreased oses after the opera- 
tion. Calcium channel inhibitors and disopyramide, if
given before the operation, were generally discontinued. 
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Fig. 1. Overall actuarial survival. 
From 1972 to 1988, patients were given warfarin for 3 to 
4 weeks as prophylaxis against thromboemboli r ginating 
from the myectomy site. Since 1988, however, aspirin 
alone has been used. 
Follow-up. Follow-up was obtained by direct patient 
interview, review of patient records, or information sup- 
plied by referring physicians. The overall mean follow-up 
period was 6.1 (_+4.8) years (range 0.1 to 19.26 years) and 
6.3 (_+5.0) years for the 109 survivors. Follow-up was 94% 
complete with a cumulative total of 956 patient-years. One 
hundred nine (69%) patients were living, 10 patients 
(6.3%) were lost to follow-up, and 39 patients (24.7%) 
were dead. Operative mortality includes any death within 
30 days after the operation. 
Statistical analysis. Actuarial survival and specific 
event-free rates were calculated by the Cutler-Ederer 
method. Preoperative and postoperative chocardio- 
graphic comparisons were done with Student's paired t 
tests. Multivariant analysis was done by Cox regression 
analysis. 
Results 
Early results. The overall 30-day operative mor- 
tality rate was 3.2% (5/158); for patients less than 65 
years of age it was 0.8% (1/123). The overall mor- 
tality rate for patients undergoing LVMM only was 
2.3% (3/131). Concomitant coronary artery bypass 
grafting was performed in 22 patients and mitral 
valve replacement for organic lesions of the mitral 
apparatus in five patients (two patients had LVMM, 
bypass grafting, and valve replacement). The mor- 
tality rate in patients undergoing these combined 
procedures was 7.4% (2/27). Causes of early death 
included myocardial infarction with left ventricular 
free wall rupture, myocardial failure after repair of a 
ventricular septal defect, sepsis with associated mul- 
tisystem organ failure, stroke resulting from proba- 
ble thromboembolism, and renal failure resulting 
from delayed cardiac tamponade associated with 
excessive anticoagulation. Two ventricular septal 
Table II. Preoperative hernodynarnics 
Mean 
value SD Range 
Systolic PAP (mm Hg) 37.53 _+ 18.5 12-125 
PCWP (mm Hg) 14.78 +_7.1 3-46 
LVEDP (mm Hg) 19.76 _+8.7 3-45 
CI (L/min/m 2) 2.58 _+0.77 0.7-6.9 
Max LVOT gradient (ram Hg) 117 .6  +_46.4 25-250 
Grade 
Mitral regurgitation 
No. of 
patients 
1+ 41 
2+ 35 
3+ 17 
4+ 11 
PAP, Pulmonary artery pressure; PCWP, pulmonary capillary wedge 
pressure; LVEDP, left ventricular end-diastolic pressure; CI, cardiac index; 
Max LVOT gradient, maximum provocable l ft ventricular outflow tract 
gradient; SD, standard deviation. 
perforations (1.3%) were recognized at the time of 
LVMM and were repaired via a right ventriculot- 
omy. Congestive heart failure developed approxi- 
mately 2 months after LVMM in one additional 
patient and a ventricular septal defect was discov- 
ered. This was closed with a patch without difficulty, 
but several weeks after discharge the patient died of 
a stroke during an episode of atrial fibrillation. Four 
patients (2.5%) required permanent pacemaker 
placement for complete heart block; notably, three 
of these patients had complete right bundle branch 
block before the operation. 
The overall mean cardiopulmonary b pass time 
was 62.8 (+29.8) minutes (range 33 to 229), and for 
the LVMM only patients it was 53.1 (+_14.3) min- 
utes (range 33 to 125 minutes). The overall mean 
aortic crossclamp time was 27.1 (+_17.3) minutes 
(range 11 to 131 minutes), and for the LVMM only 
patients it was 20.9 (+_6.8) minutes (range 11 to 54 
minutes). 
Multivariate analysis identified advanced age, 
New York Heart Association functional class IV, 
and elevated mean pulmonary artery pressures as 
independent predictors of operative death (p = 
0.0068). 
Late results. Actuarial survival rates at 1, 5, 10, 
and 15 years were 92.4% (+_2.2%), 85.4% (+3.1%), 
71,5% (+_4.9%), and 46% (+_9%), respectively (Fig. 
1). Specific event-free rates at 10 and 19 years were 
94.6% (+_2.41%) and 94.6% (+2.41%) for sudden 
death, 82.3% (+4%) and 67.5% (+_11.3%) for non- 
cardiac related death, and 86.9% (+_3.6%) and 
58.4% (+_10.7%) for cardiac related death. The 
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Table III. Non-cardiac related late deaths 
I. Birth to 20 years 
Suicide/accident 
II. 21-40 years 
Suicide/accident 
III. 41-60 years 
Other ARH (not CNS) 
Pneumonia 
Malignancy 
GI disease 
Liver failure 
Respiratory insufficiency 
Unknown 
IV. 61-80 years 
Pneumonia 
Sepsis 
Malignancy 
Renal failure 
Liver failure 
Total 
1 
2 
2 
1 
1 
18 
L/V,, Age quartiles; AR/~, anticoagulation-related hemorrhage: CNS, cen- 
tral nervous system; GI, gastrointestinal. 
overall linearized cardiac related death rate for 
discharged patients was 1.7%/pt-yr. Causes of late 
cardiac related death included congestive heart fail- 
ure (n = 6), sudden unexplained eath (n = 3), 
documented ventricular tachyarrhythmias (n = 2), 
myocardial infarction (n = 2) (both in patients with 
preoperatively identified coronary artery disease), 
stroke (n = 2) (both patients had mitral prostheses 
and one was in atrial fibrillation), and hemorrhage 
associated with oral anticoagulation ( = 1). The 
linearized sudden death rate was 0.5%/pt-yr. None 
of the sudden deaths occurred in the eight patients 
with a preoperative history of cardiac arrest. 
Only age and documented coronary artery disease 
were identified by multivariate analysis as indepen- 
dent correlates of late cardiac related death. The 
impact of these determinants was further examined 
by analysis of survival according to the division of 
patients into 20-year intervals of age at operation 
(i.e., birth to 20, 21 to 40, 41 to 60, and 61 to 80 
years) (Fig. 2). In the youngest group (n = 9), no 
operative deaths occurred; survivals at 5, 10, and 15 
years were 66% (_+2.1%), 66% (_+2.1%), and 66% 
(_+2.1%), respectively. One of three late deaths was 
cardiac related (none sudden). Similarly, in patients 
21 to 40 years of age (n = 38), no operative deaths 
occurred, and survivals at 5, 10, and 15 years were 
97% (-+2.8%), 97% (_+2.8%), and 97% (_+2.8%), 
respectively. The only late death was not cardiac 
related. Likewise, in patients 41 to 60 years of age 
(n = 62), there were no operative deaths, and 
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Fig. 2. Actuarial survival by age at the time of operation. 
survivals at 5, 10, and 15 years were 86% (_+5%), 
71% (_+7%), and 38% (_+15%), respectively. Six of 
23 late deaths were cardiac related (one sudden and 
five the result of congestive heart failure). All five 
operative deaths occurred in the 61 to 80 year group 
(49 patients, 10.2% operative mortality rate). Late 
survivals at 5, 10, and 15 years were 89% (_+5%), 
56% (+11%), and 24% (-+14%), respectively. 
Twelve of 19 late deaths were cardiac related (three 
sudden, four congestive heart failure, one myocar- 
dial infarction, four thromboembolic). Thus opera- 
tive deaths in this series were confined to the group 
of older patients (>60 years), and the majority of 
late cardiac deaths also occurred in this group. 
Late non-cardiac related deaths. Eighteen late 
deaths were not cardiac related. The causes are 
summarized in Table III. 
Correlation of outcome with echocardiographic 
data. Preoperatively, the mean diastolic IVS thick- 
ness for all patients was 2.2 cm (_+0.61), the LVPW 
thickness 1.4 cm (_+0.4), and the mean IVS/LVPW 
ratio 1.7 (_+0.6). Neither operative risk (death or 
septal perforation) nor quality of late outcome (e.g., 
late death or worsening of preoperative symptoms 
after the operation) correlated significantly with 
these variables. Specifically, in the two patients with 
ventricular septal defects created at operation, the 
measured IVS thickness was not significantly differ- 
ent from that of the overall group mean. Operative 
survivors dichotomized into subgroups above and 
below the mean (or median) for IVS thickness, 
LVPW thickness, or IVS/LVPW ratio showed sim- 
ilar distributions for functional improvement and 
for cardiac related death, including sudden death. 
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Table IV. Preoperative and postoperative two- 
dimensional transthoracic echocardiographic values 
Early Late 
Measurement Preop. postop, postop. 
IVS 2.19 -+ 0.61 1.91 -+ 0.68* 1.74 +- 0.52* 
LVPW 1.39 -+ 0.40 1.38 -- 0.45 1.32 -+ 0.41 
IVS/LVPW 1.67 -+ 0.58 1.49 -+ 0.69* 1.41 -+ 0.43* 
Rest gradient 66.82 _+ 39 20.2 -+ 23* 8.2 _+ 14" 
Max gradient 85.72 _+ 36 41.6 -- 28* 22.8 -+ 27 
IVS, Interventricular septum; LVPW, left ventricular posterior wall; Max, 
maximum provocable, 
*/7 < 0,05 versus preoperative alue. 
Patients with absent or low LVOT gradients. 
There were 31 patients with LVOT gradients less 
than 20 mm Hg at rest, as measured by catheteriza- 
tion (before 1984) or by Doppler technique (in the 
absence of catheterization data). All, however, had 
provocable LVOT gradients greater than 36 mm 
Hg. Actuarial survivals and extent of functional 
benefit for these patients did not differ significantly 
from those for patients with higher gradients at rest. 
Midventricular obstruction. Fourteen patients in 
this series preoperatively had "midventricular obstruc- 
tion" as indicated by the appearance of the IVS on 
two-dimensional study and Doppler localization of the 
major shift in LVOT flow velocity. At operation, this 
variant form was confirmed by inspection of the IVS 
insofar as the most prominent extent of hypertrophic 
septum was situated below the subaortic location. 
LVMM was accordingly modified to fully traverse this 
region. The results, in terms of relief of obstruction 
and long-term clinical improvement, did not differ 
significantly from those obtained in patients with more 
typical subaortic hypertrophy. 
Serial echocardiographic studies. The results of 
preoperative and early and late postoperative two- 
dimensional transthoracic echocardiographic data 
are summarized in Table IV. The mean time to late 
postoperative xamination was 36.18 (+_45.99) 
months (range 0.20 to 180.75 months). Postopera- 
tive studies showed significant decreases in IVS 
thickness and LVOT gradient; no patient exhibited 
a significant residual LVOT gradient persistent over 
time. The mean value for the IVS/LVPW in these 
serially studied patients also decreased, and this 
change was statistically significant at the early and 
late postoperative studies. 
Discussion 
The symptoms of most patients with HOCM 
respond favorably to negative inotropic medication. 
Verapamil continues to be the most effective drug, 
with sustained improvement in symptoms in over 
half of treated patients] Symptomatic improvement 
is related to both a decrease in LVOT gradient and 
improvement in left ventricular diastolic relaxation 
with a resulting increase in left ventricular end- 
diastolic volume without an increase in left ventric- 
ular pressure, s However, an estimated 15% to 25% 
of patients with hypertrophic cardiomyopathy ave 
a poor response to medical treatment or become 
unresponsive tomedical therapy and have tradition- 
ally been considered candidates for transaortic 
LVMM.9, a0 The majority of these patients have high 
LVOT gradients at rest or on provocation. Vera- 
pamil should be used cautiously in this subset of 
patients because of concern regarding exacerbation 
of LVOT gradient as a result of vasodilatation. 11 
Seilar and colleagues 12suggested that LVMM 
improved 10-year actuarial survival of patients with 
HOCM as compared with medical therapy alone; 
this supports a previous report by Rothlin and 
coworkers. 13 Survival of patients with the combina- 
tion of surgical resection and long-term postopera- 
tive verapamil was better than operative therapy 
alone. The authors acknowledged the limitations of 
the retrospective method of analysis and recognized 
that the various groups were not really comparable. 
However, no prospective, randomized study to as- 
sess the efficacy of medical versus surgical or com- 
bined therapy for HOCM exists or is likely to be 
conducted. Regardless, the literature generally sup- 
ports the effectiveness of surgical treatment for 
medically unresponsive, symptomatic HOCM. 9' 11, 14 
Surgical treatment of HOCM is designed to im- 
prove left ventricular systolic function by relief of 
LVOT obstruction. LVOT narrowing enerally oc- 
curs in a region of asymmetric septal hypertrophy. It 
is generally accepted that a Venturi effect causes 
systolic anterior motion of the anterior mitral valve 
leaflet and results in LVOT obstruction by a variable 
degree of abutment of the leaflet against he sep- 
turn. The goal of operation is to expand the cross- 
sectional area of the LVOT and thereby diminish or 
abolish systolic anterior motion of the anterior 
mitral leaflet; this simultaneously alleviates mitral 
regurgitation. The most appropriate surgical proce- 
dure to accomplish this, however, remains contro- 
versial. Cooley, 2' 15 Krajer,16 and their associates 
have used mitral valve replacement to eliminate 
obstruction, and Macintosh and colleagues 17have 
proposed selective mitral valve replacement for 
patients with measured septal thickness less than 18 
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mm; the rationale for the latter suggestion was the 
increased risk of septal perforation by LVMM in 
such patients. In our study, however, we found no 
correlation between IVS thickness and creation of a 
ventricular septal defect, and we are aware of no 
other report in the literature to support mitral valve 
replacement on the basis of this principle. Further, 
our data amply confirm the experience ofothers that 
LVMM alone dramatically reduces LVOT obstruc- 
tion and associated mitral regurgitation: ~s-2° Re- 
placement of a structurally intact mitral valve is 
unnecessary, clinically disadvantageous, and con- 
ceptually unappealing. The five patients who under- 
went mitral valve replacement in our series all had 
intrinsic valve disease that would have continued to 
impose clinically important valvular dysfunction. 
Dual-chamber pacing with ventricular preexcita- 
tion has been proposed as an alternative to surgical 
treatment of patients with medically refractory 
HOCM.3, 4, 21 Pacing results in paradoxical move- 
ment of the IVS, thereby increasing the cross- 
sectional area of the LVOT and abolishing or 
decreasing the Venturi effect responsible for systolic 
anterior motion of the mitral valve. The recent 
report by Fananapazir and associates 21 records im- 
pressive intermediate-term results with DDD pacing 
in 84 patients. Significant improvement in symptoms 
and LVOT gradients were noted at a mean interval 
of 2.3 years, with only two sudden deaths during the 
period of follow-up. Although these data are en- 
couraging, comparison of late results with those 
obtained by LVMM (e.g., 10 to 20 years) will simply 
require further follow-up. 22 It is also important to 
await the reproduction of these data by other cen- 
ters before DDD pacing can be recommended as
the treatment of choice for patients with medically 
refractory HOCM. In this regard, we would note 
that a substantial number of patients referred for 
LVMM at our institution since completion of this 
review have had implanted DDD pacing systems 
that failed to provide symptomatic relief. Thus it 
may be that this form of treatment is best suited for 
selected patients, such as the elderly. Clearly, crite- 
ria that are accurately predictive of outcome with 
DDD pacing are needed. 
Our results confirm that LVMM can be per- 
formed with a low operative mortalitY rate, particu- 
larly in younger patients. Indeed, no operative 
deaths occurred in 109 patients 60 years of age or 
younger. Only advanced age, severe congestive 
heart failure, and pulmonary hypertension were 
identified as independent correlates of operative 
death. Thus patients in the oldest age quartile (61 to 
80 years) sustain an operative mortality rate of 
10.2% (5/49 patients). This is comparable to the 
reports of others who have described operative 
mortality rates of 5% to 16% for similar subsets of 
patients. 23-26 Notably, no routine hemodynamic 
(with the exception of pulmonary artery pressures) 
or echocardiographic measurements correlated sig- 
nificantly with operative mortality. 
The reported annual mortality rate for patients 
with HOCM ranges from 2% to 4% and generally is
dominated by sudden death. 27 In our series, five 
sudden deaths occurred, yielding an overall inear- 
ized rate of 0.5%/pt-yr. None occurred in Patients 
surviving more than 5 years. None of the patients 
who died suddenly had a preoperative history of 
cardiac arrest; however, we believe that implanta- 
tion of an automatic defibrillator at the time of 
LVMM in such patients is warranted. No other 
highly specific marker exists because malignant ven- 
tricular arrhythmias can be induced by programmed 
stimulation in the great majority of patients with 
HOCM. Indeed, 17 of the patients included in the 
present report had undergone intraoperative elec- 
trophysiologic testing before cardiopulmonary b - 
pass, and sustained ventricular tachycardia or ven- 
tricular fibrillation was inducible in 14. 28 Inducibility 
of arrhythmias per se does not constitute an indica- 
tion for defibrillator implantation. 
Most of the remaining late cardiac related eaths 
were due to congestive heart failure, which may 
represent the progression of HOCM to a state of 
depressed contractility and ventricular dilatation or 
unsustainable deterioration of ventricular compli- 
ance or both. A confounding factor is myocardial 
ischemia resulting from obliterative l sions of small 
coronary arteries within hypertrophic muscle or 
from atherosclerotic obstruction of epicardial ves- 
sels, or a combination ofthese features. Often, these 
pathologic determinants cannot be discriminated. 
Altogether, 16 late deaths in our series were 
classified as cardiac related, resulting in a linearized 
death rate of 1.7%/pt-yr and, in combination with 
non-cardiac related deaths, 5-, 10-, and 15-year 
actuarial survivals of 85%, 72%, and 46%, respec- 
tively. These figures are comparable with those 
described by others, 13'~9'2°'29' even though the 
mean age of our patients was somewhat higher than 
in most previOus reports. Age at operation was 
identified by multivariate analysis as a variable 
independently associated with late death. Multivari- 
ate analysis identified coronary artery disease and 
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preoperative functional class (41 to 60 age quartile) 
and female gender (61 to 80 age quartile) as inde- 
pendent predictors of late death. In the quartiles of 
age ranging from birth to 20 and from 21 to 40 years, 
none of the preoperative variables examined corre- 
lated significantly with late mortality. This may be 
explained by the failure to examine variables that 
were important, but unavailable, or may simply 
reflect intrinsic randomness. 
LVMM resulted in improvement in functional 
class and/or symp'~oms in 95% of our surviving 
patients. This qual~,~y of outcome is similar to the 
experience of others. 2°' 30 As with survival, none of 
the hemodynamic or echocardiographic features 
analyzed correlated significantly with symptomatic 
benefit. This is somewhat surprising insofar as the 
extent of left ventricular hypertrophy was variable, 
and many patients exhibited substantial thickening 
of the LVPW before the operation and might have 
been expected to retain significant disability because 
of abnormal eft ventricular compliance. Whether 
LVMM that effectively relieves LVOT obstruction 
also ameliorates left ventricular stiffness remains 
controversial, partially because of the difficulty of 
accurately assessing left ventricular diastolic func- 
tion. In 13 patients included in the present series, 
measurements of diastolic filling velocities by pulsed 
Doppler technique suggested improvement in dia- 
stolic filling after LVMM91 Others have noted 
similar evidence suggestive of enhanced compii- 
ance14, 20; overall, however, definitive information is 
lacking because of methodologic uncertainty and 
the difficulty of differentiation between the effects of 
ischemia and intrinsic myocardial abnormalities. 
Perhaps newer approaches such as cine magnetic 
resonance imaging 32 may provide further informa- 
tion that could prove useful in clinical management 
(e.g., the selection of patients who would benefit 
from postoperative treatment with a calcium chan- 
nel blocking agent). 
Regardless of these considerations, elimination or 
reduction of LVOT obstruction by LVMM appears 
to dominate as the primary determinant of clinical 
outcome, irrespective of the primary symptom 
present before the operation. Others have been able 
to correlate persistence of symptoms with residual 
obstruction,20, 33but we were unable to establish a
statistically significant association because of the 
very small number of patients (n = 5) who reported 
no improvement. Moreover, in these five excep- 
tional patients, residual LVOT gradients as esti- 
mated by Doppler interrogation remained below 45 
mm Hg (mean 15.6, range 0 to 45 mm Hg), and 
therefore other elements of the hypertrophic disor- 
der, such as diastolic dysfunction as noted earlier or 
persistent ischemia resulting from small-vessel dis- 
ease, must be invoked. 
Overall, our experience with transaortic LVMM 
documents the reproducible fficacy of this proce- 
dure. The operative risk is low, particularly in 
younger patients, and the expectation for sustained 
relief of symptoms and improved clinical function is 
high. The long-term results of LVMM serve as an 
established standard for comparison with other 
methods of treatment of patients with medically 
refractory HOCM. 
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Discussion 
Dr. Pat O. Daily (San Diego, Calif). Your results et the 
standard for LVMM for HOCM. Your operative mortal- 
ity overall of 3.2% and 0% in 109 patients less than 60 
years of age is quite good. The survival of 85% at 5 years 
and 72% at 10 years are very good long-term results as 
well. However, the long-term period that these patients 
were evaluated, that is, from 1972 to 1995, and then your 
average follow-up of 6.1 years lead me to ask why with a 
study period of 23 years was the average follow-up 6.1 
years? 
Dr. Robbins. That reflects the number of operations 
that were done most recently. More operations have been 
done in the past few years. 
Dr. Daily. So most of the earlier patients presumably 
had died and you were not able to obtain follow-up 
information? 
Dr. Robbins. There were 39 deaths totally and only 10 
patients were lost to follow-up. I think it just means that 
more operations were performed most recently. 
Dr. Daily. You mentioned that different modalities 
besides LVMM were used to treat HOCM, one of them 
being mitral valve replacement; I suppose that is done 
primarily in Houston. Dual-chamber pacing with ventric- 
ular preexcitation is another and induced myocardial 
infarction of the inferior basal septum is yet another. With 
those last two methods, do you have any follow-up data or 
are there any data available in the literature so that one 
could compare those two methods with LVMM? 
Dr. Robhins. The last one we threw in there out of 
interest. An American Heart Association abstract pre- 
sented this year, from a cardiology group in Belgium, 
suggested that if you infarcted the basal septum then that 
part of the septum would not move and you could get an 
increase in the size of the LVOT. Interestingly, mitral 
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valve replacement was also brought forward for a subset 
of patients at the National Institutes of Health, where Dr. 
Morrow developed these techniques, by his associate 
Chuck Macintosh. He suggested that mitral valve replace- 
ment was indicated for those patients with septal dimen- 
sions less than 18 mm because in his retrospective r view 
of Dr. Morrow's data he found that the incidence of 
iatrogenic ventricular septal defects was greater. The 
cardiologists at the National Institutes of Health then 
embarked on this dual-chamber pacing concept and Lami 
Fananapazir is the man who has brought this concept 
forward. Of 84 patients in his most recent report, with a 
2-year follow-up, there was a good decrease in the LVOT 
gradient and symptomatic improvement with only two late 
sudden deaths. These are very encouraging data. Inas- 
much as there is no surgical branch left at the National 
Institutes of Health, all the patients who flock there are 
getting dual-chamber pacing. I would point out that Dr. 
Stinson performed LVMM on several patients who had 
failure of dual-chamber pacing in the past couple of years. 
Dr. Daily. You initially gave your patients warfarin 
sodium (Coumadin) for anticoagulation, and more re- 
cently in the series, aspirin. You had one episode of 
hemorrhage and one episode of embolization. Do you still 
use aspirin postoperatively in all patients? 
Dr. Robbins. From 1972 until 1988 Dr. Stinson used 
warfarin and then after a couple of anticoagulation hem- 
orrhage problems occurred he converted to aspirin. He 
still uses aspirin. 
Dr. Daily. With aspirin have you had any more coagu- 
lation problems? 
Dr. Robbins. No, he has not seen a problem with 
bleeding since then, nor any problem with any thrombo- 
emboli; probably just luck. 
Dr. Daily. You described an interesting subset of 14 
patients in whom there was some obstruction of the 
midportion of the left ventricle. You used an extended 
incision distally to divide that area. Others have used left 
ventricular free wall incisions and also a modified Konno 
procedure to deal with that kind of a problem. Have you 
used either of those two variations? 
Dr. Robhins. No, Dr. Stinson believes that by looking at 
the preoperative echocardiogram and by digitally examin- 
ing the LVOT during the operation he is able to custom- 
ize the incisions for the septal resection. No patients were 
reoperated on in this series for residual obstruction, which 
supports his approach to septal resection based on the 
preoperative echocardiogram and findings at the time of 
the operation. He also believes, and this is probably 
controversial in this day and age, that transesophageal 
echocardiography is not of much benefit o him in doing 
these operations. 
Dr. Daily. Anecdotally, I have used the modified Konno 
operation in three patients and it does facilitate reaching 
that more distal area. At the same time, you can get a very 
good result with respect to opening that part of the 
obstruction even if you have to patch that part of the 
interventricular septum. 
You described the aortic incision as the typical hockey- 
stick incision going toward the noncoronary sinus. Do you 
still use that? 
Dr. Robbins. Yes, sir. 
Dr. Daily. For the past 6 years we have been transecting 
the aorta just above the coronary ostia. It allows us to raise 
the aortic valve upward on the operating table, better to 
visualize the subvalvular area that we want to try to resect. 
We have found that to be a useful technical variation. 
On the basis of your results I would certainly suggest 
that this operation is not just the standard for other 
modalities of treatment but for others who have per- 
formed LVMM and reported their results. It is excellent. 
